Find Relugolix manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 737789-87-6, Tak-385, Orgovyx, Tak 385, 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea, Chembl1800159
Molecular Formula
C29H27F2N7O5S
Molecular Weight
623.6  g/mol
InChI Key
AOMXMOCNKJTRQP-UHFFFAOYSA-N
FDA UNII
P76B05O5V6

Relugolix
Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.
Relugolix is a Gonadotropin Releasing Hormone Receptor Antagonist. The mechanism of action of relugolix is as a Gonadotropin Releasing Hormone Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of relugolix is by means of Decreased GnRH Secretion.
1 2D Structure

Relugolix

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
2.1.2 InChI
InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)
2.1.3 InChI Key
AOMXMOCNKJTRQP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
2.2 Other Identifiers
2.2.1 UNII
P76B05O5V6
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea

2. Orgovyx

3. Tak 385

4. Tak-385

5. Tak385

2.3.2 Depositor-Supplied Synonyms

1. 737789-87-6

2. Tak-385

3. Orgovyx

4. Tak 385

5. 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea

6. Chembl1800159

7. P76b05o5v6

8. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea

9. Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-n'-methoxy-

10. Relugolix [usan:inn]

11. Unii-p76b05o5v6

12. Tak385

13. Tak-385/tak385

14. Relugolix (jan/inn)

15. Relugolix [inn]

16. Relugolix [jan]

17. Relugolix(tak-385)

18. Relugolix [usan]

19. Relugolix [who-dd]

20. Schembl778416

21. Gtpl5586

22. Relugolix [orange Book]

23. C29h27f2n7o5s

24. Dtxsid40224167

25. Rvt-601

26. Amy27916

27. Bcp21587

28. Ex-a1083

29. Myfembree Component Relugolix

30. Tak-385; Rvt-601

31. Bdbm50347982

32. Mfcd25976856

33. S5808

34. Zinc43206033

35. Cs-5917

36. Db11853

37. Relugolix Component Of Myfembree

38. Sb16721

39. Ac-35863

40. Bs-18032

41. Hy-16474

42. N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-n'-methoxyurea

43. D10888

44. A857822

45. Ryeqo (relugolix-estradiol-norethisterone Acetate)

46. Q21099000

47. 1-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea

48. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[4,5-e]pyrimidin-6-yl]phenyl]-3-methoxyurea

49. 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea;relugolix

50. 1-{4-[1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 623.6 g/mol
Molecular Formula C29H27F2N7O5S
XLogP33.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count11
Rotatable Bond Count9
Exact Mass623.17624448 g/mol
Monoisotopic Mass623.17624448 g/mol
Topological Polar Surface Area158 Ų
Heavy Atom Count44
Formal Charge0
Complexity1010
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Relugolix is indicated for the treatment of adult patients with advanced prostate cancer. In a combination product with [estradiol] and [norethindrone], relugolix is indicated for the once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.


Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer .


5 Pharmacology and Biochemistry
5.1 Pharmacology

Approximately 56% of patients achieved castrate-level testosterone concentrations (<50 ng/dL) by day 4 of therapy and 97% of patients maintain these levels through 48 weeks of therapy. Relugolix requires once-daily oral administration to maintain the desired testosterone concentrations. Androgen deprivation therapies may prolong the QTc interval and should therefore be used with caution in patients having a high baseline risk of QTc prolongation, such as those with electrolyte abnormalities, congestive heart failure, or using other medications known to prolong the QTc interval. Based on its mechanism of action and data from animal studies, relugolix may result in fetal harm if administered to pregnant females - male patients with female partners should be advised to use effective contraception throughout therapy and for 2 weeks following cessation of therapy to prevent inadvertent fetal exposure.


5.2 MeSH Pharmacological Classification

Androgen Antagonists

Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
RELUGOLIX
5.3.2 FDA UNII
P76B05O5V6
5.3.3 Pharmacological Classes
Cytochrome P450 2B6 Inducers [MoA]; Cytochrome P450 3A Inducers [MoA]; Decreased GnRH Secretion [PE]; Gonadotropin Releasing Hormone Receptor Antagonist [EPC]; Gonadotropin Releasing Hormone Receptor Antagonists [MoA]; P-Glycoprotein Inhibitors [MoA]; Breast Cancer Resistance Protein Inhibitors [MoA]
5.4 ATC Code

L02BX


L - Antineoplastic and immunomodulating agents

L02 - Endocrine therapy

L02B - Hormone antagonists and related agents

L02BX - Other hormone antagonists and related agents

L02BX04 - Relugolix


5.5 Absorption, Distribution and Excretion

Absorption

The Cmax and AUC of orally-administered relugolix increase proportionally following single doses - in contrast, with repeat dosing the AUC remains proportional to the dose while the Cmax increases greater than proportionally to the dose. Following the administration of 120mg once daily, the steady-state AUC and Cmax of relugolix were 407 ( 168) ng.hr/mL and 70 ( 65) ng/mL, respectively. The absolute oral bioavailability of relugolix is approximately 12% and the median Tmax following oral administration is 2.25 hours.


Route of Elimination

Approximately 81% of an orally administered dose was recovered in the feces, of which 4.2% was unchanged parent drug, while 4.1% of the dose was recovered in the urine, of which 2.2% remained unchanged.


Clearance

The average renal clearance of relugolix is 8 L/h with a total clearance of 26.4 L/h.


5.6 Metabolism/Metabolites

Relugolix is metabolized mainly by the CYP3A subfamily of P450 enzymes, with a smaller contribution by CYP2C8.


5.7 Biological Half-Life

The average effective half-life of relugolix is 25 hours, while the average terminal elimination half-life is 60.8 hours.


5.8 Mechanism of Action

The pathogenesis and progression of prostate cancer appear driven, at least in part, by the effects of testosterone. Androgen deprivation has been demonstrated to result in cell death and tumor regression in many well-differentiated prostate cancer cell lines - for this reason, androgen deprivation therapy (ADT) has become a standard in the treatment of prostate cancer, particularly in advanced disease. Testosterone production in males is carried out in the Leydig cells of testes and is stimulated by luteinizing hormone (LH), which itself is produced in the pituitary gland following the binding of gonadotropin-releasing hormone (GnRH) to corresponding GnRH receptors. Relugolix is a competitive antagonist of these GnRH receptors, thereby decreasing the release of LH and, ultimately, testosterone.


API SUPPLIERS

read-more
read-more

01

Moehs Iberica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Moehs Iberica

02

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

03

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Dr Reddy Company Banner

04

Shandong Loncom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Loncom Pharmaceutical company banner

05

Farmhispania

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFarmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Farmhispania

06

Porton Pharma Solutions

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Porton Company Banner

07

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

08

Lee Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Legal Affairs
Not Confirmed
arrow

Lee Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Legal Affairs
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT
blank

09

Aurisco Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Legal Affairs
Not Confirmed
arrow

Aurisco Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Legal Affairs
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Beijing Hope Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Legal Affairs
Not Confirmed
arrow

Beijing Hope Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Legal Affairs
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37795

Submission : 2022-12-23

Status : Active

Type : II

Moehs Iberica

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2024-08-05

Pay. Date : 2024-07-10

DMF Number : 39507

Submission : 2024-03-20

Status : Active

Type : II

Dr Reddy Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39995

Submission : 2024-06-14

Status : Active

Type : II

Porton Company Banner

04

Legal Affairs
Not Confirmed

04

Legal Affairs
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-07-24

Pay. Date : 2024-07-08

DMF Number : 38488

Submission : 2024-07-05

Status : Active

Type : II

blank

05

Legal Affairs
Not Confirmed

05

Legal Affairs
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-08-22

Pay. Date : 2024-07-19

DMF Number : 40209

Submission : 2024-07-25

Status : Active

Type : II

blank

07

Cipla Ltd

India

USDMF

arrow
Legal Affairs
Not Confirmed

07

Cipla Ltd

India
arrow
Legal Affairs
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-08-29

Pay. Date : 2024-08-08

DMF Number : 39608

Submission : 2024-03-29

Status : Active

Type : II

blank

08

Hetero Labs Ltd

India

USDMF

arrow
Legal Affairs
Not Confirmed

08

Legal Affairs
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-10-22

Pay. Date : 2024-09-24

DMF Number : 40410

Submission : 2024-09-27

Status : Active

Type : II

blank

09

Legal Affairs
Not Confirmed

09

Legal Affairs
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40244

Submission : 2024-07-24

Status : Inactive

Type : II

blank

10

Lee Pharma Ltd

India

USDMF

arrow
Legal Affairs
Not Confirmed

10

Legal Affairs
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37365

Submission : 2022-09-06

Status : Active

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

Lee Pharma

India
Pharmaceutical Sciences
Not Confirmed
arrow

Lee Pharma

India
arrow
Pharmaceutical Sciences
Not Confirmed

Relugolix IH

Date of Issue : 2022-06-15

Valid Till : 2025-07-28

Written Confirmation Number : WC-0186

Address of the Firm : Sy No.10/G-1, Gaddapotharam (V), Jinnaram (M), Sangareddy District, Pincode 5023...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652985000,"product":"RELUGOLIX AMINE COMPOUND(QTY:500GMS, VALUE:USD 5800)","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DFM INTERNATIONAL LIMITED","supplierCountry":"CHINA","foreign_port":"NA","customer":"DRREDDY\\'S LABORATORIES LTD","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"11600","totalValueFC":"5898.6","currency":"USD","unitRateINR":"911760","date":"20-May-2022","totalValueINR":"455880","totalValueInUsd":"5898.6","indian_port":"HYDERABAD AIR","hs_no":"29333919","bill_no":"8755204","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658428200,"product":"RELUGOLIX 2.12 KGS [ DRUG LICENCE NO:TL\/HZ\/22\/000059 DT:06.01.2022]","address":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST","city":"MUMBAI,MAHARASHTRA","supplier":"AURISCO PHARMACEUTICAL CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"NOVARTIS HEALTHCARE PRIVATE LIMITED","customerCountry":"INDIA","quantity":"2.12","actualQuantity":"2.12","unit":"KGS","unitRateFc":"12000","totalValueFC":"25898.6","currency":"USD","unitRateINR":"971400","date":"22-Jul-2022","totalValueINR":"2059368","totalValueInUsd":"25898.6","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"9675517","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669573800,"product":"RELUGOLIX API","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DFM INTERNATIONAL LIMITED","supplierCountry":"CHINA","foreign_port":"NA","customer":"DRREDDY\\'S LABORATORIES LTD","customerCountry":"INDIA","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"7725","totalValueFC":"195490.7","currency":"USD","unitRateINR":"638180.7","date":"28-Nov-2022","totalValueINR":"15954517.82","totalValueInUsd":"195490.7","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"3508675","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670265000,"product":"RELUGOLIX","address":"12TH FLOOR, COMMERZ II,,INTERNATIO NAL BUSNESS PARK,OBEROI","city":"GARDEN CITY OFF WESTERN EXPR HIGHWA","supplier":"PLUS CHEMICALS","supplierCountry":"CZECH REPUBLIC","foreign_port":"NA","customer":"WATSON PHARMA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.35","actualQuantity":"0.35","unit":"KGS","unitRateFc":"19000","totalValueFC":"7940.7","currency":"USD","unitRateINR":"1869600","date":"06-Dec-2022","totalValueINR":"654360","totalValueInUsd":"7940.7","indian_port":"BOMBAY AIR","hs_no":"29333990","bill_no":"3618169","productDescription":"API","marketType":"REGULATED MARKET","country":"CZECH REPUBLIC","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"12TH FLOOR, COMMERZ II,,INTERNATIO NAL BUSNESS PARK,OBEROI"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677090600,"product":"RELUGOLIX","address":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST","city":"MUMBAI,MAHARASHTRA","supplier":"AURISCO PHARMACEUTICAL COLTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"NOVARTIS HEALTHCARE PRIVATE LIMITED","customerCountry":"INDIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"12000","totalValueFC":"36462","currency":"USD","unitRateINR":"1003800","date":"23-Feb-2023","totalValueINR":"3011400","totalValueInUsd":"36462","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"4770524","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1681065000,"product":"INTERMEDIATES - RELUGOLIX INTERMEDIATE","address":"SCO 915, 2ND FLOOR,,NAC, MANIMAJRA ,","city":"CHANDIGARH,CHANDIGARH","supplier":"HANGZHOU LONGSHINE BIO-TECH CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"ADLEY LAB LIMITED","customerCountry":"INDIA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"14250","totalValueFC":"2881.2","currency":"USD","unitRateINR":"1180612.5","date":"10-Apr-2023","totalValueINR":"236122.5","totalValueInUsd":"2881.2","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"5455311","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SCO 915, 2ND FLOOR,,NAC, MANIMAJRA ,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1681756200,"product":"(FOC) RELUGOLIX (1 PACK X 22 KG =22 KG) (DSIR NO TU\/IV-RD\/2638\/2020 DT 28\/08\/2020)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"ACCORD HEALTHCARE LTD","supplierCountry":"GERMANY","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS LIMITED","customerCountry":"INDIA","quantity":"22.00","actualQuantity":"22","unit":"KGS","unitRateFc":"5000","totalValueFC":"117957.1","currency":"USD","unitRateINR":"439410.4","date":"18-Apr-2023","totalValueINR":"9667028.13","totalValueInUsd":"117957.1","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"5569236","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710873000,"product":"RELUGOLIX","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"AURISCO PHARMACEUTICALS CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"SANDOZ PRIVATE LIMITED","customerCountry":"INDIA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"8600","totalValueFC":"43369.9","currency":"USD","unitRateINR":"720250","date":"20-Mar-2024","totalValueINR":"3601250","totalValueInUsd":"43369.9","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"2663006","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"BADU INUSTRIAL PARK ZONEZHEJIANG PROVINCE SHANGHAICHINA CN","customerAddress":"SANDOZ HOUSE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1711909800,"product":"RELUGOLIX THF SOLVATE (R AND D PURPOSE) (SW\/ND\/CT-17\/2024\/0000042 DT 27\/02\/2024)","address":"2ND FLOOR, CHINUBHAI CENTRE,","city":"AHMEDABAD, GUJARAT","supplier":"SUMITOMO PHARMA SWITZERLAND GMBH","supplierCountry":"FRANCE","foreign_port":"PARIS - CHARLES DE G","customer":"INTAS PHARMACEUTICALS LIMITED","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"50","unit":"GMS","unitRateFc":"36.3","totalValueFC":"3416.9","currency":"USD","unitRateINR":"5706.7","date":"01-Apr-2024","totalValueINR":"285335.32","totalValueInUsd":"3416.9","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"2836798","productDescription":"API","marketType":"REGULATED MARKET","country":"FRANCE","selfForZScoreResived":"Pharma Grade","supplierPort":"PARIS - CHARLES DE G","supplierAddress":"AESCHENGRABEN 274051 BASELSDNF CH","customerAddress":"2ND FLOOR, CHINUBHAI CENTRE,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713205800,"product":"RELUGOLIX EP\/BP\/IP\/USP\/PH. EUR (RELUGOLIX) FOC","address":"2ND FLOOR, CHINUBHAI CENTRE,","city":"AHMEDABAD, GUJARAT","supplier":"ACCORD HEALTHCARE LIMITED","supplierCountry":"GERMANY","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"INTAS PHARMACEUTICALS LIMITED","customerCountry":"INDIA","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"5000","totalValueFC":"243348.7","currency":"USD","unitRateINR":"508034.8","date":"16-Apr-2024","totalValueINR":"20321391.13","totalValueInUsd":"243348.7","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"3049942","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"319 PINNER ROAD SAGE HOUSE HA1 4HFPinner, , United KingdomSDNF United Kingdom","customerAddress":"2ND FLOOR, CHINUBHAI CENTRE,"}]
20-May-2022
16-Apr-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 03, 2024

blank

01

HPAPI Summit
Not Confirmed
HPAPI Summit
Not Confirmed

Details : Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.

Product Name : Orgovyx

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 03, 2024

blank

Details:

Rexigo (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in India for testosterone suppression in patients with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Rexigo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 02, 2024

blank

02

HPAPI Summit
Not Confirmed
HPAPI Summit
Not Confirmed

Details : Rexigo (relugolix) is a nonpeptide GnRH receptor antagonist. It is launched in India for testosterone suppression in patients with advanced prostate cancer.

Product Name : Rexigo

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 02, 2024

blank

Details:

ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 24, 2023

blank

03

HPAPI Summit
Not Confirmed
HPAPI Summit
Not Confirmed

Details : ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.

Product Name : Orgovyx

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 24, 2023

blank

Details:

Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 23, 2023

blank

04

HPAPI Summit
Not Confirmed
HPAPI Summit
Not Confirmed

Details : Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.

Product Name : Orgovyx

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 23, 2023

blank

Details:

Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.


Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Myfembree

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 19, 2023

blank

05

Sumitomo

Japan
arrow
HPAPI Summit
Not Confirmed

Sumitomo

Japan
arrow
HPAPI Summit
Not Confirmed

Details : Myfembree (relugolix, estradiol, and norethindrone acetate) has received a dual indication approval, making it the first Health Canada-approved oral treatment to manage uterine fibroids and endometriosis.

Product Name : Myfembree

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 19, 2023

blank

Details:

Sumitovant and Myovant will strengthen Myovant's two products, Orgovyx® (relugolix) and Myfembree® capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Sumitovant Biopharma

Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million

Deal Type: Acquisition October 03, 2023

blank

06

HPAPI Summit
Not Confirmed
HPAPI Summit
Not Confirmed

Details : Sumitovant and Myovant will strengthen Myovant's two products, Orgovyx® (relugolix) and Myfembree® capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health.

Product Name : Orgovyx

Product Type : Other Small Molecule

Upfront Cash : $1,700.0 million

October 03, 2023

blank

Details:

Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.


Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Ryeqo

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Sumitomo

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 15, 2023

blank

07

Gedeon Richter

Hungary
arrow
HPAPI Summit
Not Confirmed

Gedeon Richter

Hungary
arrow
HPAPI Summit
Not Confirmed

Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Product Name : Ryeqo

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

September 15, 2023

blank

Details:

Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.


Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Ryeqo

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 11, 2023

blank

08

Gedeon Richter

Hungary
arrow
HPAPI Summit
Not Confirmed

Gedeon Richter

Hungary
arrow
HPAPI Summit
Not Confirmed

Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Product Name : Ryeqo

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 11, 2023

blank

Details:

Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.


Lead Product(s): Relugolix

Therapeutic Area: Oncology Brand Name: Orgovyx

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 20, 2022

blank

09

Clinigen Group

United Kingdom
arrow
HPAPI Summit
Not Confirmed

Clinigen Group

United Kingdom
arrow
HPAPI Summit
Not Confirmed

Details : Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Product Name : Orgovyx

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 20, 2022

blank

Details:

MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is the first once-daily oral treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women approved by U.S. Food and Drug Administration, with a treatment duration of upto 24 months.


Lead Product(s): Relugolix,Estradiol,Norethisterone Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Myfembree

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 04, 2022

blank

10

HPAPI Summit
Not Confirmed
HPAPI Summit
Not Confirmed

Details : MYFEMBREE (relugolix, estradiol, and norethindrone acetate) is the first once-daily oral treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women approved by U.S. Food and Drug Administration, with a treatment durati...

Product Name : Myfembree

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 04, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Accord healthcare

United Kingdom
ACS GCI
Not Confirmed
arrow

Accord healthcare

United Kingdom
arrow
ACS GCI
Not Confirmed

Relugolics

Brand Name : Orgovyx

Dosage Form : Tablet, film-coated

Dosage Strength : 120 mg

Packaging : Bottle 30item

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

Accord healthcare

United Kingdom
ACS GCI
Not Confirmed
arrow

Accord healthcare

United Kingdom
arrow
ACS GCI
Not Confirmed

Relugolixum

Brand Name : Orgovyx

Dosage Form : Filmtabl

Dosage Strength : 120mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

03

ACS GCI
Not Confirmed
arrow
arrow
ACS GCI
Not Confirmed

RELUGOLIX

Brand Name : ORGOVYX

Dosage Form : TABLET;ORAL

Dosage Strength : 120MG

Packaging :

Approval Date : 2020-12-18

Application Number : 214621

Regulatory Info : RX

Registration Country : USA

blank

04

ACS GCI
Not Confirmed
arrow
arrow
ACS GCI
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Brand Name : MYFEMBREE

Dosage Form : TABLET;ORAL

Dosage Strength : 1MG;0.5MG;40MG

Packaging :

Approval Date : 2021-05-26

Application Number : 214846

Regulatory Info : RX

Registration Country : USA

blank

05

Country
ACS GCI
Not Confirmed
arrow

Country
arrow
ACS GCI
Not Confirmed

RELUGOLIX

Brand Name : ORGOVYX

Dosage Form : TABLET

Dosage Strength : 120MG

Packaging :

Approval Date :

Application Number : 2542137

Regulatory Info : Prescription

Registration Country : Canada

blank

06

Country
ACS GCI
Not Confirmed
arrow

Country
arrow
ACS GCI
Not Confirmed

RELUGOLIX

Brand Name : MYFEMBREE

Dosage Form : TABLET

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number : 2541742

Regulatory Info : Prescription

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

ACS GCI
Not Confirmed
arrow
arrow
ACS GCI
Not Confirmed

RELUGOLIX

Brand Name : ORGOVYX

Dosage Form : TABLET;ORAL

Dosage Strength : 120MG

Approval Date : 2020-12-18

Application Number : 214621

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

02

ACS GCI
Not Confirmed
arrow
arrow
ACS GCI
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Brand Name : MYFEMBREE

Dosage Form : TABLET;ORAL

Dosage Strength : 1MG;0.5MG;40MG

Approval Date : 2021-05-26

Application Number : 214846

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Accord Healthcare S.L.U.

United Kingdom
ACS GCI
Not Confirmed
arrow

Accord Healthcare S.L.U.

United Kingdom
arrow
ACS GCI
Not Confirmed

Relugolics

Brand Name : Orgovyx

Dosage Form : Tablet, film-coated

Dosage Strength : 120 mg

Packaging : Bottle 30item

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

Accord Healthcare AG

United Kingdom
ACS GCI
Not Confirmed
arrow

Accord Healthcare AG

United Kingdom
arrow
ACS GCI
Not Confirmed

Relugolixum

Brand Name : Orgovyx

Dosage Form : Filmtabl

Dosage Strength : 120mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

SUMITOMO PHARMA SWITZERLAND GMBH

Country
ACS GCI
Not Confirmed
arrow

SUMITOMO PHARMA SWITZERLAND GMBH

Country
arrow
ACS GCI
Not Confirmed

RELUGOLIX

Brand Name : ORGOVYX

Dosage Form : TABLET

Dosage Strength : 120MG

Packaging :

Approval Date :

Application Number : 2542137

Regulatory Info : Prescription

Registration Country : Canada

blank

02

SUMITOMO PHARMA SWITZERLAND GMBH

Country
ACS GCI
Not Confirmed
arrow

SUMITOMO PHARMA SWITZERLAND GMBH

Country
arrow
ACS GCI
Not Confirmed

RELUGOLIX

Brand Name : MYFEMBREE

Dosage Form : TABLET

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number : 2541742

Regulatory Info : Prescription

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions
Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   

Impressions: 7754

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

#PharmaFlow by PHARMACOMPASS
24 Oct 2024

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

RELUGOLIX

US Patent Number : 8058280

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214621

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-01-28

blank

02

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

RELUGOLIX

US Patent Number : 12097198

Drug Substance Claim :

Drug Product Claim :

Application Number : 214621

Patent Use Code : U-3020

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank

03

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

RELUGOLIX

US Patent Number : 10350170

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 214621

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-02-25

blank

04

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

RELUGOLIX

US Patent Number : 7300935

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 214621

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-01-28

blank

05

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

US Patent Number : 11793812

Drug Substance Claim :

Drug Product Claim :

Application Number : 214846

Patent Use Code : U-2360

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-05-03

blank

06

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

US Patent Number : 11957684

Drug Substance Claim :

Drug Product Claim :

Application Number : 214846

Patent Use Code : U-3129

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank

07

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

US Patent Number : 8058280

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214846

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-01-28

blank

08

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

US Patent Number : 11033551

Drug Substance Claim :

Drug Product Claim :

Application Number : 214846

Patent Use Code : U-3129

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank

09

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

RELUGOLIX

US Patent Number : 11583526

Drug Substance Claim :

Drug Product Claim :

Application Number : 214621

Patent Use Code : U-3020

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank

10

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

RELUGOLIX

US Patent Number : 10786501

Drug Substance Claim :

Drug Product Claim :

Application Number : 214621

Patent Use Code : U-3020

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-09-29

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
World Vape Show
Not Confirmed
arrow
World Vape Show
Not Confirmed

RELUGOLIX

Exclusivity Code : NCE

Exclusivity Expiration Date : 2025-12-18

Application Number : 214621

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 737789-87-6 / Relugolix API manufacturers, exporters & distributors?

Relugolix manufacturers, exporters & distributors 1

41

PharmaCompass offers a list of Relugolix API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Relugolix manufacturer or Relugolix supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Relugolix manufacturer or Relugolix supplier.

PharmaCompass also assists you with knowing the Relugolix API Price utilized in the formulation of products. Relugolix API Price is not always fixed or binding as the Relugolix Price is obtained through a variety of data sources. The Relugolix Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Relugolix

Synonyms

737789-87-6, Tak-385, Orgovyx, Tak 385, 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea, Chembl1800159

Cas Number

737789-87-6

Unique Ingredient Identifier (UNII)

P76B05O5V6

About Relugolix

Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- Manufacturers

A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-, including repackagers and relabelers. The FDA regulates Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- Suppliers

A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- supplier is an individual or a company that provides Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- active pharmaceutical ingredient (API) or Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- finished formulations upon request. The Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers may include Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- API manufacturers, exporters, distributors and traders.

click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USDMF

A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- DMF (Drug Master File) is a document detailing the whole manufacturing process of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- active pharmaceutical ingredient (API) in detail. Different forms of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- DMFs exist exist since differing nations have different regulations, such as Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- DMF submitted to regulatory agencies in the US is known as a USDMF. Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USDMF includes data on Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers with USDMF on PharmaCompass.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- WC

A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- written confirmation (Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- WC) is an official document issued by a regulatory agency to a Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- manufacturer, verifying that the manufacturing facility of a Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- APIs or Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- finished pharmaceutical products to another nation, regulatory agencies frequently require a Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- WC (written confirmation) as part of the regulatory process.

click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers with Written Confirmation (WC) on PharmaCompass.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- suppliers with NDC on PharmaCompass.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- GMP

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- GMP manufacturer or Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- GMP API supplier for your needs.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- CoA

A Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- CoA (Certificate of Analysis) is a formal document that attests to Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-'s compliance with Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- specifications and serves as a tool for batch-level quality control.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- CoA mostly includes findings from lab analyses of a specific batch. For each Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- may be tested according to a variety of international standards, such as European Pharmacopoeia (Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- EP), Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty